INDOSAT
28.2.2023 11:55:38 CET | Business Wire | Press release
President Director and CEO of Indosat Ooredoo Hutchison (Indosat), Vikram Sinha, discussed the story of Indosat, the most successfully merger that empowers Indonesia. Indosat is the new world-class digital telecoms and internet company for Indonesia resulting from the merger of Indosat Ooredoo and Hutchison 3 Indonesia.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228005739/en/
Vikram Sinha, President Director and CEO of Indosat Ooredoo Hutchison (Photo: Business Wire)
During the roundtable discussion, Sinha highlighted that telco mergers often fail for various reasons, such as difficulty integrating different technologies and systems, regulatory hurdles, and challenges in retaining key personnel and customers. However, Indosat's successful merger has transformed the telecommunications industry and Indonesia's GDP growth.
Indonesia is one of the fastest-growing economies in the world and one of the most prominent digital economies in ASEAN. Digital adoption enables Indonesia to reduce the time to realize its long-term goal of achieving high-income status. Indosat, a digital telco with 100 million subscribers, is transforming rapidly to help drive the digital revolution in the country.
Sinha discussed how the merger of Indosat Ooredoo and Hutchison 3 Indonesia had exceeded all expectations for 2022, giving a positive outlook for Indonesia's market and the opportunity to grow in the telco industry. Indosat has an ongoing 9-quarter integration plan, and the realization of their synergies is running smoothly and has been completed ahead of the plan. Using Multi-Operator Core Networks (MOCN) technology, their network integration is targeted to be completed this quarter.
Indosat launched a research report titled Empowering Indonesia 2023, which reviews the pillars of Indonesia's digital economy and the role of technology in accelerating its future growth. The report shows that Indosat is the primary driver of the telecommunications industry and Indonesia's GDP growth, fueled by its solid growth in 2022.
Indosat's Full-Year 2022 Result shows a solid performance both financially and operationally. Total revenue increased by 48.9% YoY, EBITDA was recorded at Rp19,468.7 billion, and net profit for the year attributable to parent company owners was Rp4,723.4 billion, normalized net profit increased by 76.2% YoY. The company's cellular customers increased by 62.5% to 102.2 million for FY 2022.
"We have defied expectations and become the successful merger in the world. Indosat is not just good for the industry; it's good for Indonesia. We will continue to drive the digital revolution and create value for all our stakeholders," said Vikram Sinha, President Director and CEO of Indosat Ooredoo Hutchison.
About Indosat Ooredoo Hutchison
Indosat Ooredoo Hutchison (IDX: ISAT)’s vision is to become the most preferred digital telco of Indonesia. Through its world-class digital telecom services and preeminent network, Indosat Ooredoo Hutchison strives to connect and empower every Indonesian. Jointly controlled by Ooredoo Group and CK Hutchison, Indosat Ooredoo Hutchison was formed through the merger of PT Indosat Tbk and PT Hutchison 3 Indonesia in 2022.
Website: www.IOH.co.id
YouTube: https://www.youtube.com/channel/UChs2x7pZ2D8UgHz9cgrn3sQ
Facebook: https://www.facebook.com/indosat
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005739/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom